

**Experiment Number:** 99037-03

**Test Type:** 90-DAY

**Route:** GAVAGE

**Species/Strain:** Rat/F 344/N

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

**Test Compound:** alpha/beta Thujone mixture

**CAS Number:** 76231-76-0

**Date Report Requested:** 10/20/2014

**Time Report Requested:** 16:22:49

**First Dose M/F:** NA / NA

**Lab:** SRI

<b>C Number:</b>	C99037B
<b>Lock Date:</b>	04/04/2003
<b>Cage Range:</b>	All
<b>Date Range:</b>	All
<b>Reasons For Removal:</b>	All
<b>Removal Date Range:</b>	All
<b>Treatment Groups:</b>	All
<b>Study Gender:</b>	Both
<b>PWG Approval Date</b>	NONE

Experiment Number: 99037-03

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: alpha/beta Thujone mixture

Time Report Requested: 16:22:49

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: SRI

F 344/N Rat MALE	0	MG/KG	12.5	MG/KG	25	MG/KG	50	MG/KG	75	MG/KG	100	MG/KG
<b>Disposition Summary</b>												
Animals Initially In Study	10		10		10		10		10		10	
Early Deaths												
Natural Death									2		7	
Survivors												
Natural Death											1	
Terminal Sacrifice	10		10		10		10		8		2	
Animals Examined Microscopically	10		10		10		10		10		10	
<b>ALIMENTARY SYSTEM</b>												
Esophagus	(10)		(0)		(0)		(0)		(10)		(10)	
Intestine Large, Cecum	(10)		(0)		(0)		(0)		(10)		(9)	
Hemorrhage											1 (11%)	
Inflammation, Chronic Active											1 (11%)	
Intestine Large, Colon	(10)		(0)		(0)		(0)		(9)		(9)	
Intestine Large, Rectum	(10)		(0)		(0)		(0)		(10)		(9)	
Intestine Small, Duodenum	(10)		(0)		(0)		(0)		(10)		(9)	
Intestine Small, Ileum	(10)		(0)		(0)		(0)		(8)		(8)	
Intestine Small, Jejunum	(10)		(0)		(0)		(0)		(8)		(6)	
Liver	(10)		(3)		(0)		(2)		(10)		(10)	
Clear Cell Focus									1 (10%)			
Hematopoietic Cell Proliferation	3 (30%)								2 (20%)		1 (10%)	
Hepatodiaphragmatic Nodule	4 (40%)		3 (100%)				1 (50%)		1 (10%)		2 (20%)	
Inflammation, Chronic							1 (50%)		1 (10%)		1 (10%)	
Vacuolization Cytoplasmic	5 (50%)								3 (30%)			
Mesentery	(1)		(0)		(0)		(0)		(0)		(0)	
Accessory Spleen	1 (100%)											
Pancreas	(10)		(0)		(0)		(0)		(10)		(10)	
Acinus, Vacuolization Cytoplasmic									1 (10%)		2 (20%)	
Atrophy											1 (10%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99037-03

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: alpha/beta Thujone mixture

Time Report Requested: 16:22:50

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: SRI

F 344/N Rat MALE	0	MG/KG	12.5	MG/KG	25	MG/KG	50	MG/KG	75	MG/KG	100	MG/KG
Salivary Glands	(10)		(0)		(0)		(0)		(10)		(10)	
Parotid Gl, Basophilic Focus	9 (90%)								4 (40%)		5 (50%)	
Stomach, Forestomach	(10)		(10)		(10)		(10)		(10)		(10)	
Degeneration, Cystic									1 (10%)		1 (10%)	
Hyperplasia, Squamous									1 (10%)		1 (10%)	
Stomach, Glandular	(10)		(10)		(10)		(10)		(10)		(10)	
Edema									1 (10%)		1 (10%)	
Erosion, Focal											1 (10%)	
Hemorrhage									1 (10%)		1 (10%)	
Inflammation, Chronic									1 (10%)			
Pigmentation											1 (10%)	
Ulcer									1 (10%)		1 (10%)	
CARDIOVASCULAR SYSTEM												
Heart	(10)		(0)		(0)		(0)		(10)		(10)	
Cardiomyopathy	6 (60%)								8 (80%)		2 (20%)	
ENDOCRINE SYSTEM												
Adrenal Cortex	(10)		(10)		(10)		(10)		(10)		(10)	
Accessory Adrenal Cortical Nodule					1 (10%)							
Hypertrophy							1 (10%)				1 (10%)	
Adrenal Medulla	(10)		(0)		(10)		(10)		(10)		(10)	
Parathyroid Gland	(10)		(0)		(0)		(0)		(10)		(10)	
Pituitary Gland	(10)		(0)		(10)		(10)		(10)		(10)	
Angiectasis									1 (10%)		1 (10%)	
Pars Distalis, Atrophy									1 (10%)		2 (20%)	
Pars Distalis, Hemorrhage											1 (10%)	
Pars Distalis, Necrosis											1 (10%)	
Rathkes Cleft, Dilatation	1 (10%)						1 (10%)		3 (30%)		4 (40%)	
Thyroid Gland	(10)		(0)		(0)		(0)		(10)		(10)	
Ultimobranchial Cyst	1 (10%)										1 (10%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99037-03

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Rat/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: alpha/beta Thujone mixture

CAS Number: 76231-76-0

Date Report Requested: 10/20/2014

Time Report Requested: 16:22:50

First Dose M/F: NA / NA

Lab: SRI

F 344/N Rat MALE	0	MG/KG	12.5	MG/KG	25	MG/KG	50	MG/KG	75	MG/KG	100	MG/KG
GENERAL BODY SYSTEM												
None												
GENITAL SYSTEM												
Epididymis	(10)		(0)		(0)		(0)		(10)		(10)	
Preputial Gland	(10)		(0)		(0)		(0)		(10)		(10)	
Prostate	(10)		(0)		(0)		(0)		(10)		(10)	
Infiltration Cellular, Mixed Cell	1 (10%)											
Seminal Vesicle	(10)		(0)		(0)		(0)		(10)		(10)	
Testes	(10)		(0)		(0)		(0)		(10)		(10)	
HEMATOPOIETIC SYSTEM												
Bone Marrow	(10)		(0)		(0)		(0)		(10)		(10)	
Lymph Node	(0)		(0)		(0)		(0)		(0)		(2)	
Hyperplasia, Lymphoid											1 (50%)	
Pancreatic, Hemorrhage											1 (50%)	
Lymph Node, Mandibular	(1)		(0)		(0)		(0)		(0)		(0)	
Lymph Node, Mesenteric	(10)		(0)		(0)		(0)		(10)		(10)	
Spleen	(10)		(0)		(0)		(0)		(10)		(10)	
Congestion											4 (40%)	
Pigmentation, Hemosiderin											1 (10%)	
Thymus	(10)		(0)		(0)		(0)		(10)		(10)	
Hemorrhage	1 (10%)								4 (40%)		6 (60%)	
INTEGUMENTARY SYSTEM												
Mammary Gland	(10)		(0)		(0)		(0)		(7)		(8)	
Skin	(10)		(0)		(0)		(0)		(10)		(10)	
MUSCULOSKELETAL SYSTEM												
Bone	(10)		(0)		(0)		(0)		(10)		(10)	
Skeletal Muscle	(10)		(0)		(0)		(0)		(2)		(10)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99037-03

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Rat/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: alpha/beta Thujone mixture

CAS Number: 76231-76-0

Date Report Requested: 10/20/2014

Time Report Requested: 16:22:50

First Dose M/F: NA / NA

Lab: SRI

F 344/N Rat MALE	0	MG/KG	12.5	MG/KG	25	MG/KG	50	MG/KG	75	MG/KG	100	MG/KG
NERVOUS SYSTEM												
Brain	(10)		(10)		(10)		(10)		(10)		(10)	
Congestion									2 (20%)		6 (60%)	
Hemorrhage									2 (20%)		4 (40%)	
Pigmentation	1 (10%)											
Peripheral Nerve	(10)		(0)		(0)		(0)		(2)		(10)	
Spinal Cord	(10)		(0)		(0)		(0)		(2)		(10)	
RESPIRATORY SYSTEM												
Lung	(10)		(0)		(0)		(0)		(10)		(10)	
Congestion									1 (10%)		8 (80%)	
Hemorrhage	7 (70%)								4 (40%)			
Inflammation, Acute											1 (10%)	
Inflammation, Chronic	1 (10%)											
Nose	(10)		(0)		(0)		(0)		(10)		(10)	
Olfactory Epi, Degeneration									1 (10%)			
Trachea	(10)		(0)		(0)		(0)		(10)		(10)	
SPECIAL SENSES SYSTEM												
Eye	(10)		(0)		(0)		(0)		(10)		(10)	
Harderian Gland	(10)		(0)		(0)		(0)		(10)		(10)	
Hemorrhage	1 (10%)											
Inflammation, Acute	1 (10%)											
URINARY SYSTEM												
Kidney	(10)		(10)		(10)		(10)		(10)		(10)	
Nephropathy	8 (80%)		10 (100%)		10 (100%)		10 (100%)		9 (90%)		9 (90%)	
Renal Tubule, Mineralization	1 (10%)		1 (10%)		2 (20%)		1 (10%)		1 (10%)		3 (30%)	
Renal Tubule, Necrosis											1 (10%)	
Urinary Bladder	(10)		(0)		(0)		(0)		(10)		(10)	

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 99037-03

**Test Type:** 90-DAY

**Route:** GAVAGE

**Species/Strain:** Rat/F 344/N

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

**Test Compound:** alpha/beta Thujone mixture

**CAS Number:** 76231-76-0

**Date Report Requested:** 10/20/2014

**Time Report Requested:** 16:22:50

**First Dose M/F:** NA / NA

**Lab:** SRI

\*\*\*END OF MALE DATA\*\*\*

Experiment Number: 99037-03

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: alpha/beta Thujone mixture

Time Report Requested: 16:22:50

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: SRI

F 344/N Rat FEMALE	0	MG/KG	12.5	MG/KG	25	MG/KG	50	MG/KG	75	MG/KG	100	MG/KG
<b>Disposition Summary</b>												
Animals Initially In Study	10		10		10		10		10		10	
Early Deaths												
Natural Death									8		9	
Survivors												
Terminal Sacrifice	10		10		10		10		2		1	
Animals Examined Microscopically	10		10		10		10		10		10	
<b>ALIMENTARY SYSTEM</b>												
Esophagus	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Cecum	(10)		(0)		(0)		(10)		(9)		(10)	
Intestine Large, Colon	(10)		(0)		(0)		(10)		(10)		(10)	
Hemorrhage									1 (10%)			
Intestine Large, Rectum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Duodenum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Ileum	(10)		(0)		(0)		(10)		(8)		(9)	
Intestine Small, Jejunum	(10)		(0)		(0)		(10)		(9)		(10)	
Liver	(10)		(1)		(2)		(10)		(10)		(10)	
Hematopoietic Cell Proliferation	2 (20%)						4 (40%)		2 (20%)		1 (10%)	
Hepatodiaphragmatic Nodule	1 (10%)		1 (100%)		2 (100%)		2 (20%)		1 (10%)			
Inflammation, Chronic	6 (60%)											
Necrosis									1 (10%)			
Vacuolization Cytoplasmic									2 (20%)			
Pancreas	(10)		(0)		(0)		(10)		(10)		(10)	
Acinus, Vacuolization Cytoplasmic									1 (10%)			
Inflammation, Chronic											1 (10%)	
Salivary Glands	(10)		(0)		(0)		(10)		(10)		(10)	
Parotid GI, Basophilic Focus	4 (40%)						6 (60%)		3 (30%)		9 (90%)	
Parotid GI, Necrosis, Focal	1 (10%)											
Stomach, Forestomach	(10)		(10)		(10)		(10)		(10)		(10)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99037-03

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: alpha/beta Thujone mixture

Time Report Requested: 16:22:50

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: SRI

F 344/N Rat FEMALE	0	MG/KG	12.5	MG/KG	25	MG/KG	50	MG/KG	75	MG/KG	100	MG/KG
Degeneration, Cystic									1 (10%)		1 (10%)	
Edema									1 (10%)			
Stomach, Glandular	(10)		(10)		(10)		(10)		(10)		(10)	
Edema									1 (10%)		3 (30%)	
Hemorrhage											2 (20%)	
Infiltration Cellular, Eosinophil							1 (10%)					
Inflammation, Chronic							1 (10%)					
Mineralization							1 (10%)					
CARDIOVASCULAR SYSTEM												
Heart	(10)		(0)		(0)		(10)		(10)		(10)	
Cardiomyopathy	2 (20%)						1 (10%)				2 (20%)	
ENDOCRINE SYSTEM												
Adrenal Cortex	(10)		(10)		(10)		(10)		(10)		(10)	
Adrenal Medulla	(10)		(10)		(10)		(10)		(10)		(10)	
Parathyroid Gland	(10)		(0)		(0)		(9)		(10)		(8)	
Pituitary Gland	(10)		(10)		(10)		(10)		(10)		(10)	
Angiectasis									1 (10%)		1 (10%)	
Congestion							1 (10%)					
Pars Distalis, Atrophy									3 (30%)		3 (30%)	
Pars Distalis, Necrosis							1 (10%)		1 (10%)			
Rathkes Cleft, Dilatation					1 (10%)		5 (50%)		4 (40%)		5 (50%)	
Thyroid Gland	(10)		(0)		(0)		(10)		(10)		(10)	
Ectopic Thymus							1 (10%)		1 (10%)			
GENERAL BODY SYSTEM												
None												
GENITAL SYSTEM												
Clitoral Gland	(10)		(0)		(0)		(10)		(10)		(10)	
Ovary	(10)		(10)		(10)		(10)		(10)		(10)	

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 99037-03

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: alpha/beta Thujone mixture

Time Report Requested: 16:22:50

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: SRI

F 344/N Rat FEMALE	0	MG/KG	12.5	MG/KG	25	MG/KG	50	MG/KG	75	MG/KG	100	MG/KG
Cyst	2 (20%)		2 (20%)				1 (10%)					
Uterus	(10)		(3)		(1)		(10)		(10)		(10)	
Dilatation	2 (20%)		2 (67%)		1 (100%)		1 (10%)				1 (10%)	
Vagina	(10)		(10)		(10)		(10)		(10)		(10)	
Cyst			1 (10%)									
HEMATOPOIETIC SYSTEM												
Bone Marrow	(10)		(0)		(0)		(10)		(10)		(10)	
Lymph Node	(0)		(1)		(3)		(2)		(0)		(1)	
Hemorrhage					1 (33%)		1 (50%)					
Hyperplasia, Lymphoid			1 (100%)									
Pancreatic, Hemorrhage							2 (100%)				1 (100%)	
Pancreatic, Infiltration Cellular, Histiocyte					2 (67%)							
Lymph Node, Mesenteric	(10)		(0)		(0)		(10)		(10)		(10)	
Hyperplasia, Lymphoid							1 (10%)		1 (10%)			
Spleen	(10)		(0)		(0)		(10)		(10)		(10)	
Atrophy									1 (10%)		1 (10%)	
Thymus	(10)		(0)		(0)		(10)		(10)		(10)	
Hemorrhage									4 (40%)		4 (40%)	
INTEGUMENTARY SYSTEM												
Mammary Gland	(10)		(0)		(0)		(10)		(10)		(10)	
Skin	(10)		(0)		(0)		(10)		(10)		(10)	
MUSCULOSKELETAL SYSTEM												
Bone	(10)		(0)		(0)		(10)		(10)		(10)	
Skeletal Muscle	(10)		(0)		(0)		(0)		(2)		(10)	
NERVOUS SYSTEM												
Brain	(10)		(10)		(10)		(10)		(10)		(10)	
Congestion									3 (30%)		8 (80%)	
Hemorrhage									4 (40%)		3 (30%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99037-03

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: alpha/beta Thujone mixture

Time Report Requested: 16:22:50

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: SRI

F 344/N Rat FEMALE	0	MG/KG	12.5	MG/KG	25	MG/KG	50	MG/KG	75	MG/KG	100	MG/KG
Pigmentation					1 (10%)		6 (60%)		5 (50%)		4 (40%)	
Peripheral Nerve	(10)		(0)		(0)		(0)		(2)		(10)	
Spinal Cord	(10)		(0)		(0)		(0)		(4)		(10)	
Congestion											2 (20%)	
RESPIRATORY SYSTEM												
Lung	(10)		(0)		(0)		(10)		(10)		(10)	
Alveolus, Infiltration Cellular, Histiocyte, Focal	1 (10%)								1 (10%)			
Congestion									2 (20%)		4 (40%)	
Hemorrhage	8 (80%)						3 (30%)					
Nose	(10)		(0)		(0)		(10)		(10)		(10)	
Trachea	(10)		(0)		(0)		(10)		(10)		(10)	
SPECIAL SENSES SYSTEM												
Eye	(10)		(0)		(0)		(10)		(10)		(10)	
Harderian Gland	(10)		(0)		(0)		(10)		(10)		(10)	
URINARY SYSTEM												
Kidney	(10)		(10)		(10)		(10)		(10)		(10)	
Nephropathy					1 (10%)		3 (30%)		2 (20%)		3 (30%)	
Renal Tubule, Degeneration											1 (10%)	
Renal Tubule, Mineralization	3 (30%)		8 (80%)		8 (80%)		8 (80%)		10 (100%)		9 (90%)	
Renal Tubule, Necrosis									1 (10%)			
Urinary Bladder	(10)		(0)		(0)		(10)		(10)		(10)	

\*\* END OF REPORT \*\*

a - Number of animals examined microscopically at site and number of animals with lesion